A Unifying Hypothesis for Familial and Sporadic Alzheimer's Disease

Alzheimer's disease (AD) is characterised by the aggregation of two quite different proteins, namely, amyloid-beta (Aβ), which forms extracellular plaques, and tau, the main component of cytoplasmic neurofibrillary tangles. The amyloid hypothesis proposes that Aβ plaques precede tangle formation but there is still much controversy concerning the order of events and the linkage between Aβ and tau alterations is still unknown. Mathematical modelling has become an essential tool for generating and evaluating hypotheses involving complex systems. We have therefore used this approach to discover the most probable pathway linking Aβ and tau. The model supports a complex pathway linking Aβ and tau via GSK3β, p53, and oxidative stress. Importantly, the pathway contains a cycle with multiple points of entry. It is this property of the pathway which enables the model to be consistent with both the amyloid hypothesis for familial AD and a more complex pathway for sporadic forms.

[1]  Jesús Avila,et al.  GSK3: A possible link between beta amyloid peptide and tau protein , 2010, Experimental Neurology.

[2]  John Hardy,et al.  The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal , 2009, Journal of neurochemistry.

[3]  Xi Chen,et al.  Materials and Methods Som Text Figs. S1 and S2 Table S1 References Abad Directly Links A␤ to Mitochondrial Toxicity in Alzheimer's Disease , 2022 .

[4]  Ling Song,et al.  Glycogen Synthase Kinase-3β (GSK3β) Binds to and Promotes the Actions of p53* , 2003, Journal of Biological Chemistry.

[5]  P. Dolan,et al.  Truncated tau and Aβ cooperatively impair mitochondria in primary neurons , 2012, Neurobiology of Aging.

[6]  Scott A. Small,et al.  Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis , 2008, Neuron.

[7]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[8]  Xi Chen,et al.  ABAD enhances Aβ‐induced cell stress via mitochondrial dysfunction , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  R. Katzman.,et al.  Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques , 1988, Annals of neurology.

[10]  Hiroaki Kitano,et al.  The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models , 2003, Bioinform..

[11]  D. Wilkinson,et al.  Towards an e-biology of ageing: integrating theory and data , 2003, Nature Reviews Molecular Cell Biology.

[12]  Simon Lovestone,et al.  The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.

[13]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[14]  Carole J Proctor,et al.  GSK3 and p53 - is there a link in Alzheimer's disease? , 2010, Molecular Neurodegeneration.

[15]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[16]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[17]  Linda Partridge,et al.  Inhibition of GSK-3 Ameliorates Aβ Pathology in an Adult-Onset Drosophila Model of Alzheimer's Disease , 2010, PLoS genetics.

[18]  Carole J. Proctor,et al.  Explaining oscillations and variability in the p53-Mdm2 system , 2008, BMC Systems Biology.

[19]  Simon Lovestone,et al.  p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells , 2007, Neuroscience Letters.

[20]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[21]  D. Gillespie.  Exact Stochastic Simulation of Coupled Chemical Reactions , 1977 .

[22]  Jacky L. Snoep,et al.  BioModels Database: a free, centralized database of curated, published, quantitative kinetic models of biochemical and cellular systems , 2005, Nucleic Acids Res..

[23]  L. Lue,et al.  Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .

[24]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[25]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[26]  Pravir Kumar,et al.  The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. , 2009, Molecular biology of the cell.

[27]  L. Moran,et al.  Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson’s disease , 2006, Neurogenetics.

[28]  Dave Morgan,et al.  Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation , 2003, The Journal of Neuroscience.